Year
2025
Authors
DE POUVOURVILLE Gérard, Bailey M. Doyinsola, Farge Gaëlle, Mohanty Salini, Breau-Brunel Manon, Roy Gem, de Wazieres Benoit, Janssen Cécile, Tauty Solenne, Bugnard Françoise, Goguillot Mélanie, Bénard Stève, Johnson Kelly D.
Abstract
Pneumococcal disease (PD) is associated with high morbidity and mortality, specifically among individuals ≥65 years of age and those with underlying medical conditions (UMCs). This retrospective cohort study estimated the clinical burden of PD in adults ≥18 years of age with or without UMCs in France. Data were obtained from the French National Health Data System for four yearly cohorts (1 January 2015-31 December 2018). Characteristics of patients with UMCs, with or without PD (UMC population), and the incidence rate and lethality rate of PD leading to hospitalization (in-patient PD population), stratified by age and risk status, were described. In the UMC population (n = 7,947,622; mean age: 65 years), the incidence rate of in-patient PD episodes was 121.98 per 100,000 person-years and was highest among individuals ≥65 years of age (138.52) and in those considered medium-risk (102.45) or high-risk (165.77). In the in-patient PD population (n = 41,885), 59.6% were ≥65 years of age; 1-year all-cause mortality following the initial in-patient PD episode was 26.5%. Individuals ≥65 years of age (regardless of risk status) had a higher risk of PD leading to hospitalization than individuals 18-64 years of age. This study shows a high burden of PD in France due to in-patient PD among adults with UMCs, particularly in those ≥65 years of age, despite their eligibility for pneumococcal vaccination. This highlights the need for higher vaccination coverage, supported by the recent extension of vaccination to all people ≥65 years of age, regardless of their health risk status.
BAILEY, M.D., FARGE, G., MOHANTY, S., BREAU-BRUNEL, M., ROY, G., DE POUVOURVILLE, G. … JOHNSON, K.D. (2025). Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study. Human Vaccines & Immunotherapeutics, 21(1), pp. 2515760.